2021 Latest Design Hydroxybutanoate - 5-Fluorocytosine (5-FC) CAS 2022-85-7 Purity ≥99.5% (HPLC) Capecitabine Emtricitabine Intermediate – Ruifu

Manufacturer with High Purity and Stable Quality
Commercial Supply Capecitabine (CAS: 154361-50-9) Related Intermediates:
5-Fluorocytosine CAS: 2022-85-7
2′,3′-Di-O-acetyl-5′-deoxy-5-fluorocytidine CAS: 161599-46-8
1,2,3-Tri-O-acetyl-5-deoxy-β-D-ribofuranose CAS: 62211-93-2
Capecitabine CAS: 154361-50-9

5-Fluorocytosine (5-FC) CAS: 2022-85-7 Analysis Method
Appearance— White or Almost White Crystalline Powder
Loss on drying —Dry it at 105 for 4 hours: it loses not more than 1.50% of its weight.
Residue on ignition—not more than 0.1%.
Heavy metals — 0.002%.
Fluoride—Mix 70 mL of freshly prepared saturated potassium chloride solution with 30 mL of isopropyl alcohol, fill the electrode with the clear supernatant, and allow the electrode to remain in the mixture for not less than 2 hours prior to use, or preferably overnight.
When taking the measurements, transfer the solution to a 150-mL beaker, and immerse the electrodes. Insert a polytef-coated stirring bar into the beaker, place the beaker on a magnetic stirrer having an insulated top, and allow to stir until equilibrium is attained (about 1 to 2 minutes). Rinse and dry the electrodes between measurements, taking care not to scratch the crystal in the specific ion electrode.
Measure the potential of each Standard preparation, and plot the fluoride concentration, in mg per 100 mL, versus the potential, in mV, on semilogarithmic paper. Measure the potential of the Test preparation, and determine from the standard curve the fluoride concentration, in mg per 100 mL. Calculate the percentage of fluoride in the portion of Flucytosine taken by the formula:
C / 10
in which C is the fluoride concentration, in mg per 100 mL, from the standard curve: not more than 0.05% of fluoride is found.
Fluorouracil— Dissolve 250 mg in 10 mL of a mixture of glacial acetic acid and water (4:1). Apply 20 µL of this solution to a thin-layer chromatographic plate coated with a 0.5-mm layer of chromatographic silica gel mixture. To the same plate apply 20 µL, in 10-µL increments, of a 0.025 mg per mL solution of USP Fluorouracil RS in a mixture of glacial acetic acid and water (4:1). Develop the chromatogram in a mixture of chloroform and glacial acetic acid (13:7) until the solvent front has moved not less than 14 cm from the origin. Remove the plate from the developing chamber, and allow the solvent to evaporate. Locate the spots on the plate by observing under short-wavelength UV radiation: any spot from the solution under test is not greater in size and intensity than the spot at the respective RF produced by the Standard solution, corresponding to not more than 0.1% of fluorouracil.
Assay— Place about 400 mg of Flucytosine, accurately weighed, in a 250-mL beaker, add 150 mL of a mixture of 2 volumes of glacial acetic acid and 1 volume of acetic anhydride, and dissolve, warming gently if necessary. Titrate potentiometrically with 0.1 N perchloric acid VS, using a calomel-glass electrode system. Perform a blank determination, and make any necessary correction. Each mL of 0.1 N perchloric acid is equivalent to 12.91 mg of C4H4FN3O. Flucytosine contains not less than 98.5 percent and not more than 101.0 percent of C4H4FN3O, calculated on the dried basis.

Package: Bottle, Aluminum foil bag, Cardboard drum, 25kg/Drum, or according to customer’s requirement.

Storage Condition: Store in sealed containers at cool and dry place; Protect from light, moisture and pest infestation.

A fluorinated pyrimidine, 5-Fluorocytosine CAS: 2022-85-7 (fluorocytosine; 5-FC), was initially developed as a potential anti-cancer agent but it was not sufficiently effective in the field of cancer chemotherapy. Later, 5-FC proved to be active in experimental candidiasis and cryptococcosis in mice and was used to treat human infections. In addition to its activity against Candida and Cryptococcus, 5-FC also has an inhibitory activity against fungi causing chromoblastomycosis; however, it is ineffective against infections caused by filamentous fungi. 5-FC has a high prevalence of primary resistance in many fungal species. Due to this primary resistance, 5-FC is used mainly in combination with other antifungals (primarily amphotericin B, AmB) and more recently it has been investigated in combination with other agents including fluconazole (FLU), ketoconazole (KTZ), itraconazole (ITRA), voriconazole (VORI) and echinocandins (e.g., micafungin, MICA and caspofungin, CAS). It is used only rarely as a single agent. Flucytosine (5-FC) is a synthetic antimycotic compound, first synthesized in 1957. It has no intrinsic antifungal capacity, but after it has been taken up by susceptible fungal cells, it is converted into 5-fluorouracil (5-FU), which is further converted to metabolites that inhibit fungal RNA and DNA synthesis. Monotherapy with 5-FC is limited because of the frequent development of resistance. 

5-Fluorocytosine CAS: 2022-85-7 is a fluorinated analog of cytosine. 5-FC is approved by the U.S. Food and Drug Administration (FDA) as an antifungal agent used for the treatment of Candida and Cryptococcus. Lately with the development of gene therapy, 5-FC has been introduced as a prodrug in combination with the cytosine deaminase suicide gene. 

5-Fluorocytosine CAS: 2022-85-7 is a fluorinated cytosine analog and antifungal agent. 5-fluorocytosine becomes 5-fluorouracil and is then incorporated into RNA, causing miscoding and inhibition of DNA synthesis. It is effective against Candida and Cryptococcus species and can be used as a negative selection agent in transgenic plants. 5-Fluorocytosine is often used in clinical in vitro tests known as antimicrobial susceptibility tests or ASTs to determine their efficacy against certain bacterial species. They are tested against gram-negative and gram-positive bacteria using panels, discs, and MIC strips by medical microbiologists.